Document is current
Any future updates will be listed below
-
Authors
Mora-Ortiz, Marina
Alcala-Diaz, Juan F.
Rangel-Zuñiga, Oriol Alberto
Arenas-de Larriva, Antonio Pablo
Abollo-Jimenez, Fernando
Luque-Cordoba, Diego
Priego-Capote, Feliciano
Malagon, Maria M.
Delgado-Lista, Javier
Ordovas, Jose M.
Perez-Martinez, Pablo
Camargo, Antonio
Lopez-Miranda, Jose https://orcid.org/0000-0002-8844-0718
-
Funding
Funding for this research was provided by:
Ministerio de Economia y Competitividad (AGL2012/39615, PIE14/00005, PIE14/00031, AGL2015-67896-P)
Ministerio de Economía y Competitividad (CP14/00114, PI19/00299, DTS19/00007, PI13/00023, PI16/01777)
Proyectos de Investigación de Excelencia (CVI-7450)
- License Information
-
More Information
Article History
Received: 16 May 2022
Accepted: 12 September 2022
First Online: 27 October 2022
Declarations
:
: CORDIOPREV is registered at ClinicalTrials.gov (number NCT00924937). The trial protocol and subsequent revisions were approved by the Reina Sofia University Hospital Ethics Committee (ref. number 1496/27/03/2009), following the Helsinki Declaration and good clinical practices. All patients signed a written informed consent to participate in the study.
: Not applicable.
: The authors declare that they have no competing interests.
